In contrast to a TCR, which recognizes a peptide fragment of an antigen presented by an HLA molecule on the surface of target cells, a CAR molecule recognizes an intact cell surface antigen, thus tumour cell recognition is HLA independent so there is no restriction in terms of patient selection. The gene discussed is CD53; the disease is neoplasm.